1 Min Read
May 12 (Reuters) - Loxo Oncology Inc:
* Loxo Oncology announces FDA orphan drug designation granted to larotrectinib for the treatment of solid tumors with ntrk-fusion proteins Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.